Nakao M, Tada M, Tsuchimori K, Uekata M
Pharmaceutical Research Laboratories III, Takeda Chemical Industries Ltd., Osaka, Japan.
Eur J Clin Microbiol Infect Dis. 1995 May;14(5):391-9. doi: 10.1007/BF02114894.
The activities of various types of antiulcer agents against Helicobacter pylori strains were determined by an agar dilution method. Among the compounds tested, benzimidazole proton pump inhibitors were found to have significant activity against this organism. The activity of lansoprazole was fourfold more potent than that of omeprazole and bismuth subsalicylate, with MICs ranging from 1.56 to 25 micrograms/ml. Exposure of Helicobacter pylori to lansoprazole led to an extensive loss of viability as well as suppression of virulence factors such as motility, adhesiveness to epithelial cells and urease activity. The combination of lansoprazole with antimicrobial agents such as penicillins, cephalosporins, macrolides, tetracyclines, aminoglycosides, quinolones, metronidazole and bismuth subsalicylate generally had an additive effect on inhibition of Helicobacter pylori growth.
采用琼脂稀释法测定了各类抗溃疡药物对幽门螺杆菌菌株的活性。在所测试的化合物中，发现苯并咪唑质子泵抑制剂对该生物体具有显著活性。兰索拉唑的活性比奥美拉唑和次水杨酸铋强四倍，其最低抑菌浓度范围为1.56至25微克/毫升。幽门螺杆菌暴露于兰索拉唑会导致活力大幅丧失，同时抑制诸如运动性、对上皮细胞的粘附性和脲酶活性等毒力因子。兰索拉唑与抗菌药物如青霉素、头孢菌素、大环内酯类、四环素类、氨基糖苷类、喹诺酮类、甲硝唑和次水杨酸铋联合使用，通常对抑制幽门螺杆菌生长具有相加作用。
